An Analyst Just Declared Eli Lilly the "Clear Winner" of an American Diabetes Association Conference Focused on Weight-Loss Drugs. Novo's Chief Scientist Disagrees. Who's Right?
Yahoo Finance ·
In the eyes of Wall Street, Eli Lilly ( LLY +1.96% ) continues to cement its lead over the competition in the field of weight-loss and diabetes drugs. After revealing a pair of positive developments coinciding with the American Diabetes Association's annual Scientific Sessions meeting this month, RBC analyst Trung Huynh declared the drugmaker the "clear winner" of the event. Yet while a glance at that statement may suggest that Eli Lilly competitors, most notably Novo Nordisk ( NVO +0.76% ) , were clear "losers" at the event, you may want to check first with Martin Holst Lange, Novo's chief science officer. Lange's remarks at the conference suggest that while Eli Lilly may have won the latest battles, the GLP-1 wars are far from finished. Let's take a closer look at the implications for both of these GLP-1 stocks . Considering the trial data unveiled during the recent conference, the RBC analyst did not make his bold remarks regarding Eli Lilly's purported victory at the ADA conference lightly.
DYAX Investor Sentiment
Bullish (Long) 51% · Bearish (Short) 49%
538 participants
Related News
- First Trust Mid Cap Core AlphaDEX Fund declares quarterly distribution of $0.2660
- First Trust Mid Cap Value AlphaDEX Fund declares quarterly distribution of $0.1676
- FT Vest Rising Dividend Achievers Target Income ETF declares monthly distribution of $0.2040
- First Trust Large Cap Core AlphaDEX Fund declares quarterly distribution of $0.2669
- Braskem files for emergency protection against creditors as debt talks drag on
- First Trust Multi Cap Value AlphaDEX Fund declares quarterly distribution of $0.3468